通过MAP3K9的ubiquitination,CBLB调节了MAPK-P38路径,以抑制GBM细胞的入侵和迁移
Yuankun Liu1,2, Kaixiang Ni1,2, Songyun Zhao1,2
1Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Journal of cellular physiology
|April 21, 2025
概括
研究人员发现,在质母细胞瘤 (GBM) 中,CBLB是ubiquitin-proteasome系统的一个组成部分,是下调调节的. 恢复CBLB通过降解MAP3K9来抑制GBM细胞入侵,提供一种潜在的新GBM疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 质母细胞瘤 (GBM) 是高度侵入性和抗标准治疗,导致预后不佳.
- 无素-蛋白酶体系统 (UPS) 调节蛋白质降解,并与GBM进展有关.
- 在UPS中确定新的治疗点对于改善GBM治疗结果至关重要.
研究的目的:
- 调查E3无素结合酶CBLB在质母细胞瘤 (GBM) 中的作用.
- 阐明CBLB影响GBM细胞攻击性的分子机制.
- 评估针对GBM中CBLB的治疗潜力.
主要方法:
- 对GBM组织中CBLB表达的分析和与临床数据的相关性.
- 在体外和体内实验中评估CBLB对GBM细胞迁移和入侵的影响.
- 同免疫沉和无处不在测试以确定CBLB和MAP3K9.9之间的相互作用.
- 西方涂抹分析蛋白质水平和通路激活.
主要成果:
- 与正常脑组织相比,CBLB在GBM中显著下调,与恶性瘤和不良预后相关.
- 在实验室和体内,CBLB过度表达抑制了GBM细胞迁移和入侵.
- CBLB与MAP3K9直接相互作用,促进其K48-K63结合的多基化和随后的蛋白质体降解.
- 由于CBLB对MAP3K9进行了下调,导致MAPK-P38信号通路的激活被抑制.
结论:
- 通过抑制细胞入侵和迁移,CBLB作为GBM中的瘤抑制剂起作用.
- 该机制涉及CBLB介导的MAP3K9的泛化和降解,从而调节MAPK-P38通路.
- 在GBM治疗中,CBLB代表了一个有前途的新型治疗标.
相关概念视频
Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K
MAPK Signaling Cascades
4.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
4.9K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
The Intrinsic Apoptotic Pathway
5.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.6K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


